Pfizer main points mRNA flu vaccine information, however revises timeline
Pfizer’s mRNA flu vaccine met each primary finishissues within the 18- to 64-year-old popul. a.tion in an onpassing Section III trial, the companew york announced on Tuesday morning. However, executives are not
